These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 20814000)

  • 1. Strokes with minor symptoms: an exploratory analysis of the National Institute of Neurological Disorders and Stroke recombinant tissue plasminogen activator trials.
    Khatri P; Kleindorfer DO; Yeatts SD; Saver JL; Levine SR; Lyden PD; Moomaw CJ; Palesch YY; Jauch EC; Broderick JP
    Stroke; 2010 Nov; 41(11):2581-6. PubMed ID: 20814000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant tissue plasminogen activator for minor strokes: the National Institute of Neurological Disorders and Stroke rt-PA Stroke Study experience.
    National Institute of Neurological Disorders Stroke rt-PA Stroke Study Group
    Ann Emerg Med; 2005 Sep; 46(3):243-52. PubMed ID: 16126134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute Ischemic Stroke with Very Early Clinical Improvement: A National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Trials Exploratory Analysis.
    Balucani C; Levine SR; Khoury JC; Khatri P; Saver JL; Broderick JP
    J Stroke Cerebrovasc Dis; 2016 Apr; 25(4):894-901. PubMed ID: 26825352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A matching algorithm to address imbalances in study populations: application to the National Institute of Neurological Diseases and Stroke Recombinant Tissue Plasminogen Activator acute stroke trial.
    Mandava P; Kalkonde YV; Rochat RH; Kent TA
    Stroke; 2010 Apr; 41(4):765-70. PubMed ID: 20167911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. To treat or not to treat? Pilot survey for minor and rapidly improving stroke.
    Balucani C; Bianchi R; Feldmann E; Weedon J; Kolychev D; Levine SR
    Stroke; 2015 Mar; 46(3):874-6. PubMed ID: 25604250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of imbalances in baseline stroke severity on outcome in the National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study.
    Kwiatkowski T; Libman R; Tilley BC; Lewandowski C; Grotta JC; Lyden P; Levine SR; Brott T;
    Ann Emerg Med; 2005 Apr; 45(4):377-84. PubMed ID: 15795715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dissociation of severity of stroke and aphasia recovery early after intravenous recombinant tissue plasminogen activator thrombolysis.
    Kremer C; Kappelin J; Perren F
    J Clin Neurosci; 2014 Oct; 21(10):1828-30. PubMed ID: 24852905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A modified National Institutes of Health Stroke Scale for use in stroke clinical trials: preliminary reliability and validity.
    Lyden PD; Lu M; Levine SR; Brott TG; Broderick J;
    Stroke; 2001 Jun; 32(6):1310-7. PubMed ID: 11387492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Explicit consideration of baseline factors to assess recombinant tissue-type plasminogen activator response with respect to race and sex.
    Mandava P; Murthy SB; Munoz M; McGuire D; Simon RP; Alexandrov AV; Albright KC; Boehme AK; Martin-Schild S; Martini S; Kent TA
    Stroke; 2013 Jun; 44(6):1525-31. PubMed ID: 23674524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simple clinical predictors of stroke outcome based on National Institutes of Health Stroke scale score during 1-h recombinant tissue-type plasminogen activator infusion.
    Osaki M; Miyashita F; Koga M; Fukuda M; Shigehatake Y; Nagatsuka K; Minematsu K; Toyoda K
    Eur J Neurol; 2014 Mar; 21(3):411-8. PubMed ID: 24200315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of the National Institute of Neurological Disorders and Stroke tissue plasminogen activator studies following European Cooperative Acute Stroke Study III patient selection criteria.
    Hemmen TM; Rapp KS; Emond JA; Raman R; Lyden PD
    J Stroke Cerebrovasc Dis; 2010; 19(4):290-3. PubMed ID: 20471855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting major neurological improvement with intravenous recombinant tissue plasminogen activator treatment of stroke.
    Brown DL; Johnston KC; Wagner DP; Haley EC
    Stroke; 2004 Jan; 35(1):147-50. PubMed ID: 14657446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of serial biochemical markers with acute ischemic stroke: the National Institute of Neurological Disorders and Stroke recombinant tissue plasminogen activator Stroke Study.
    Jauch EC; Lindsell C; Broderick J; Fagan SC; Tilley BC; Levine SR;
    Stroke; 2006 Oct; 37(10):2508-13. PubMed ID: 16960091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of minor stroke definitions for thrombolysis decision making.
    Park TH; Hong KS; Choi JC; Song P; Lee JS; Lee J; Park JM; Kang K; Lee KB; Cho YJ; Saposnik G; Han MK; Bae HJ
    J Stroke Cerebrovasc Dis; 2013 May; 22(4):482-90. PubMed ID: 23545318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tenecteplase-tissue-type plasminogen activator evaluation for minor ischemic stroke with proven occlusion.
    Coutts SB; Dubuc V; Mandzia J; Kenney C; Demchuk AM; Smith EE; Subramaniam S; Goyal M; Patil S; Menon BK; Barber PA; Dowlatshahi D; Field T; Asdaghi N; Camden MC; Hill MD;
    Stroke; 2015 Mar; 46(3):769-74. PubMed ID: 25677596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intra-arterial third-generation recombinant tissue plasminogen activator (reteplase) for acute ischemic stroke.
    Qureshi AI; Ali Z; Suri MF; Kim SH; Shatla AA; Ringer AJ; Lopes DK; Guterman LR; Hopkins LN
    Neurosurgery; 2001 Jul; 49(1):41-8; discussion 48-50. PubMed ID: 11440458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How important is surrogate consent for stroke research?
    Flaherty ML; Karlawish J; Khoury JC; Kleindorfer D; Woo D; Broderick JP
    Neurology; 2008 Nov; 71(20):1566-71. PubMed ID: 18753472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thirty Years After the National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Trial: A New Era for Stroke Therapy.
    Carandang RA
    JAMA Neurol; 2016 Mar; 73(3):265-7. PubMed ID: 26810152
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of tissue plasminogen activator for acute ischemic stroke at one year. National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group.
    Kwiatkowski TG; Libman RB; Frankel M; Tilley BC; Morgenstern LB; Lu M; Broderick JP; Lewandowski CA; Marler JR; Levine SR; Brott T
    N Engl J Med; 1999 Jun; 340(23):1781-7. PubMed ID: 10362821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective, open-label safety study of intravenous recombinant tissue plasminogen activator in wake-up stroke.
    Barreto AD; Fanale CV; Alexandrov AV; Gaffney KC; Vahidy FS; Nguyen CB; Sarraj A; Rahbar M; Grotta JC; Savitz SI;
    Ann Neurol; 2016 Aug; 80(2):211-8. PubMed ID: 27273860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.